Location: Foreign Animal Disease Research
Project Number: 8064-32000-060-13-N
Project Type: Non-Funded Cooperative Agreement
Start Date: Jun 1, 2017
End Date: May 31, 2022
ARS, PIADC and Institute of Agriculture and Food Research and Technology (IRTA) through its Animal Health Program located in the CReSA Center will work together, leveraging resources and capabilities towards the rational development of novel and/or improved vaccines strains of Classical Swine Fever Virus (CSFV) and African Swine Fever Virus (ASFV) using recombinant virus technology and corresponding tests. ARS, PIADC and IRTA will enter into distinct cooperative agreements to further joint research efforts and when funding opportunities dictate.
1. The development of ELISA DIVA tests based on the CSFV antigenically marked vaccine strains developed by ARS, PIADC. Specific objectives include: A. ARS, PIADC will provide expertise in the development of CSFV live attenuated vaccine (LAV). Antigenically marked LAVs candidate FlagT4Gv developed by ARS, PIADC will be used as templated to develop a DIVA compatible assay. ARS, PIADC will provide sera from FlagT4Gv immunized animals to be used in the development of the DIVA test. B. IRTA will provide expertise in the development of the DIVA ELISA test. IRTA will design, develop and optimize the DIVA test using recombinant proteins and sera provided by ARS. 2. Technologies to be applied will include the development of attenuated ASFV strains by homologous recombination with improved safety profile. These virus strains will be built upon current knowledge applied at ARS, PIADC and IRTA in terms of genetic manipulation of virus genome towards the attenuation of ASFV. Specific objectives include: A. ARS, PIADC will provide expertise in the development of ASFV live attenuated vaccine strains. Modification of ASF strains will be by performed by genetic manipulation of virus genome and homologous recombination methodology. ARS, PIADC will produce pilot experiments towards the evaluation of attenuation and immunogenicity of the developed viruses. B. IRTA will provide expertise in the development ASFV recombinant viruses. IRTA will design and help in the development of novel attenuated strains based on the template of vaccine strains already developed by IRTA. IRTA will also participate in evaluating protective effect of the developed vaccine strains.